This newsletter presents you the following key sessions:
1. Podcast with dr. Antonio D'Alessio about real-world use of atezolizumab plus bevacizumab in patients with
hepatocellular carcinoma and Child-Pugh A and B cirrhosis
2. Nivolumab plus chemotherapy as standard first-line treatment option for patients with advanced gastric
and oesophageal cancers
3. Oxaliplatin not recommended in initial therapy for elderly patients with metastatic colorectal cancer
4. Addition of durvalumab to gemcitabine-cisplatin significantly improves outcomes in first-line advanced
biliary tract cancer
5. Adagrasib monotherapy effective in patients with pancreatic and other gastrointestinal tumours harbouring
a KRASG12C mutation